Navigation Links
Prozac Reduces Disease Activity in MS Patients
Date:4/30/2008

Small study finds antidepressant cut inflammation in relapsing remitting illness

WEDNESDAY, April 30 (HealthDay News) -- Prozac may help reduce disease activity in people with the relapsing remitting form of multiple sclerosis (MS), a new study suggests.

Forty patients with the disease were randomly selected to receive either 20 milligrams a day of fluoxetine (Prozac) or a placebo for 24 weeks. MRI brain scans were conducted every four weeks to monitor the patients for new areas of neurological inflammation, a hallmark of disease activity.

Of the 38 patients (19 in each group) who completed the study, those who took the placebo had more new areas of inflammation (average of more than five areas) than those who took the drug (average of just under two).

One in four scans from patients treated with fluoxetine showed new areas of inflammation, compared with four out of 10 scans from patients taking the placebo. During the last 16 weeks of treatment, 63 percent of patients in the fluoxetine group had no new areas of inflammation, compared with 26 percent of those in the placebo group.

The findings were published online in the Journal of Neurology Neurosurgery and Psychiatry.

This was a small study, and larger studies are needed before any firm conclusions about the use of fluoxetine in patients with relapsing remitting MS can be made, the study authors noted.

However, the findings are "sufficiently encouraging to justify further studies with fluoxetine in patients with MS," they said, and added that higher doses and treatment combinations with other drugs that alter the immune response should be considered in future studies.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.



-- Robert Preidt



SOURCE: BMJ Specialist Journals, news release, May 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Prozac Makes Old Brain Cells Young
2. Staff Training Reduces Postpartum Bleeding, Episiotomies
3. Gene Therapy in Rats Reduces Cocaine Use
4. Study shows pine bark naturally reduces osteoarthritis
5. Study Shows Pine Bark Naturally Reduces Osteoarthritis
6. Gene therapy reduces cocaine use in rats
7. Pill Reduces Relapses in MS Patients
8. Essential Nutrient Found in Eggs Reduces Risk of Breast Cancer by 24 Percent
9. Essential nutrient found in eggs reduces risk of breast cancer by 24 percent
10. Psychological intervention reduces postembolization pain
11. Aspirin Reduces Asthma Risk Among Older Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical ... neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse ... is a newly patented safety device secured by nasal surgeons onto the floor of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
Breaking Medicine Technology: